News Novartis files CAR-T in Europe in broader use than Gilead ri... Swiss pharma chasing EU licence in NHL and ALL indications
News Novartis files CAR-T in lymphoma, sets up rivalry with Gilea... Swiss pharma to compete with Gilead in non-Hodgkin lymphoma
News Gilead gains CAR-T approval, undercuts rival's headline pric... Cancer cell therapy approved for aggressive blood cancer
News AbiVax claims progress towards HIV cure French biotech to step up clinical development of ABX464.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
